caa a22 4500 465789714 CHVBK 20180323112020.0 cr unu---uuuuu 170327e19900301xx s 000 0 eng 10.1007/BF00171984 doi (NATIONALLICENCE)springer-10.1007/BF00171984 A phase I and pharmacokinetic study of intravenous vinzolidine [Elektronische Daten] [Charles Taylor, Sydney Salmon, Winston Satterlee, Aurelia Robertone, Thomas McCloskey, Mark Holdsworth, Patricia Plezia, David Alberts] Summary: The semi-synthetic vinca alkaloid vinzolidine was administered to advanced cancer patients as an intravenous bolus on a three day schedule every 21 days. Forty-two patients were treated in this phase I trial. Five partial remissions (breast-1, melanoma-2, renal cancer-2) were seen in 30 evaluable patients. The dose limiting toxicities were myelosuppression and neuropathy. Erratic myelosuppression from course to course within the same patient as seen in previous trials with oral vinzolidine, was not observed with the intravenous formulation. The measured pharmacokinetic parameters conformed best to a 2-compartment model with a mean terminal half-life of 23 hours. The anti-tumor activity observed during this phase I trial and acceptable toxicity provide the basis for initiating phase II studies in selected forms of cancer. Kluwer Academic Publishers, 1990 vinzolidine nationallicence phase I nationallicence pharmacokinetics nationallicence melanoma nationallicence renal cancer nationallicence Taylor Charles Section of Hematology/Oncology, Department of Internal Medicine and the Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, Arizona, USA aut Salmon Sydney Section of Hematology/Oncology, Department of Internal Medicine and the Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, Arizona, USA aut Satterlee Winston Lilly Research Laboratories, Eli Lilly Company, 46285, Indianapolis, Indiana, USA aut Robertone Aurelia Section of Hematology/Oncology, Department of Internal Medicine and the Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, Arizona, USA aut McCloskey Thomas Section of Hematology/Oncology, Department of Internal Medicine and the Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, Arizona, USA aut Holdsworth Mark Section of Hematology/Oncology, Department of Internal Medicine and the Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, Arizona, USA aut Plezia Patricia Section of Hematology/Oncology, Department of Internal Medicine and the Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, Arizona, USA aut Alberts David Section of Hematology/Oncology, Department of Internal Medicine and the Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, Arizona, USA aut Investigational New Drugs Kluwer Academic Publishers 8(1990-03-01), S51-S57 0167-6997 8<S51 1990 8 10637 https://doi.org/10.1007/BF00171984 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00171984 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Taylor Charles Section of Hematology/Oncology, Department of Internal Medicine and the Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, Arizona, USA aut NATIONALLICENCE 700 1- Salmon Sydney Section of Hematology/Oncology, Department of Internal Medicine and the Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, Arizona, USA aut NATIONALLICENCE 700 1- Satterlee Winston Lilly Research Laboratories, Eli Lilly Company, 46285, Indianapolis, Indiana, USA aut NATIONALLICENCE 700 1- Robertone Aurelia Section of Hematology/Oncology, Department of Internal Medicine and the Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, Arizona, USA aut NATIONALLICENCE 700 1- McCloskey Thomas Section of Hematology/Oncology, Department of Internal Medicine and the Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, Arizona, USA aut NATIONALLICENCE 700 1- Holdsworth Mark Section of Hematology/Oncology, Department of Internal Medicine and the Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, Arizona, USA aut NATIONALLICENCE 700 1- Plezia Patricia Section of Hematology/Oncology, Department of Internal Medicine and the Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, Arizona, USA aut NATIONALLICENCE 700 1- Alberts David Section of Hematology/Oncology, Department of Internal Medicine and the Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, Arizona, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8(1990-03-01), S51-S57 0167-6997 8<S51 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer